Scarica l'app Stockscreener
0.00
100.00%
-1.71
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - The Manila Times
(APS) Comprehensive Trading Strategy Report (APS:CA) - news.stocktradersdaily.com
Aptose Announces Deferral of Interest Payment | APTOF Stock News - GuruFocus
Aptose Announces Deferral of Interest Payment - Yahoo Finance
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Provides Corporate Updates - The Manila Times
Aptose Provides Corporate Updates | APTOF Stock News - GuruFocus
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose's Closing of US$3M Investment by Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences completes Public Offering of Common Shares for US$74.2M - McCarthy Tétrault
Aptose Biosciences Inc. enters into exclusive license agreement with Hanmi Pharmaceutical - McCarthy Tétrault
Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement - McCarthy Tétrault
Aptose Biosciences Inc. announces it entered into a $25M Committed Equity Facility - McCarthy Tétrault
Aptose Biosciences Inc. enters into at-the-market sales agreement with Cantor Fitzgerald & Co. - McCarthy Tétrault
Aptose Biosciences Inc. closes C$8M public offering - McCarthy Tétrault
Aptose enters equity distribution agreement with Piper Sandler and Canaccord Genuity - McCarthy Tétrault
Aptose Announces Results from Annual and Special Meeting of Shar - GuruFocus
Aptose Announces Results from Annual and Special Meeting of Shareholders - The Globe and Mail
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Trading (APS) With Integrated Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com - Defense World
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee | APTOF Stock N - GuruFocus
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - The Manila Times
(APS) Advanced Equity Analysis (APS:CA) - news.stocktradersdaily.com
Aptose Selected for Prestigious Oral Presentation of Data from T - GuruFocus
Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - St. Catharines Standard
StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences Reports Q1 2025 Financial Results - TipRanks
(APS) On The My Stocks Page (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences: Q1 Earnings Snapshot - CT Insider
Aptose Biosciences Reports Promising AML Trial Results and Expands Market Presence - TipRanks
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports First Quarter 2025 Results - The Manila Times
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):